A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Colitis Ulcerative, Ulcerative Colitis

In brief

The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.

Key facts

Study ID
NCT07463183
Run by
Merck Sharp & Dohme LLC
People needed
100
Starts
2026-03-24
Expected to finish
2028-12-21
Last updated by the study team
2026-07-31

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.